secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055608
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q1 revenue $14.8M (+64% YoY); 79% gross margin; raises $55M
--------------------------------------------------------------------

- Total revenue $14.8M (+64% YoY); Lung Diagnostic revenue $13.8M (+60%) on 11,900 test volume (+57%).
- Gross margin 79% vs 65% YoY; net loss improved 27% to $13.6M.
- Adjusted EBITDA loss $7.0M, improvement of 48% from $13.4M loss in Q1 2023.
- Raised $55M gross proceeds in April 2024 oversubscribed offering; cash $11.5M at Q1 end excluding proceeds.
- Reaffirmed 2024 revenue guidance of $65M-$68M; new collaboration with MSKCC for cancer diagnostics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017024055608/0000950170-24-055608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017024055608/bdsx-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer